Most Read Psychiatry Articles on JAMA Network

• Prescription Opioid Use and Risk for Major Depressive Disorder November 11, 2020
  This mendelian randomization analysis investigates the potential bidirectional associations between the genetic liability for prescription opioid and other nonopioid pain medications and both major depressive disorder and anxiety and stress-related disorders using genetically based methods
• Five Things to Know When a Psychiatric Patient Is Prescribed Opioids for Pain November 11, 2020
  This essay describes how psychiatrists can play an important role in optimizing care for patients who have been prescribed opioids for chronic pain.
• Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia November 4, 2020
  This Viewpoint reviews reports that relied on 4 genetic methods capable of addressing the nature of the cannabis-schizophrenia association.
• Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression—Quo Vadis? November 4, 2020
  In this issue of JAMA Psychiatry, Davis and colleagues at the Johns Hopkins Center for Psychedelic and Consciousness Research have contributed a timely and important proof-of-concept randomized clinical trial on the effects of psilocybin-assisted supportive psychotherapy for the treatment of major depression. The authors reported rapid relief of depressive symptoms and high rates of response […]
• Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Product in an Open-Label Trial November 4, 2020
  This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.